Trump is promising big changes at the FDA — here’s how drugs are approved today

Trump is promising big changes at the FDA — here’s how drugs are approved today

At least one of President Trump’s possible picks to head the Food and Drug Administration has a radical idea for when drugs should come to market.

Jim O’Neill, managing director at Mithril Capital, has said that he is in favor of approving drugs that are proven to be safe, even before they’re shown to be actually effective.

Regardless of who Trump picks in the end, his interest in cutting regulation at the FDA is clear.

“We’re going to be cutting regulations at a level that nobody’s ever seen before,” Trump said in a meeting with pharma executives on January 31. He estimated up to 80% of regulations will be slashed.

The FDA is responsible for regulating food and drugs. It’s also responsible for regulating medical devices, blood donations, veterinary products, cosmetics, and tobacco. Trump’s comments have left the drug industry concerned about what that deregulation could mean for the drug approval process.

As it exists right now, the FDA approval process can be a long and expensive. Here’s a look at how it works currently.

Skye Gould/Business Insider

Before a drug makes it to the FDA, the company has to show how it works in animals. Scientists run tests on different animals, and in the end bring that data to the FDA in the form of an Investigational New Drug application. If the FDA signs off, the company starts testing the drug in humans.

The FDA isn’t gathering that data or running the trials. That’s the responsibility of the drugmaker. The agency is just there to review it.

Skye Gould/Business Insider

That’s when phase one begins. During this trial, drugmakers administer the drug to a group of healthy humans who don’t have the disease. They’re just determining if the drug is safe. Researchers can see if the drug is toxic at higher levels and figure out if there are any major side effects that would become a problem in later trials.

These trials tend to be small, with roughly 20 to 80 participants, according to the FDA.

Skye Gould/Business Insider

Like phase one, the second trial tests whether a drug is safe, but this time the drug is given to people who have the disease, rather than healthy people.

This trial is “randomized.” That means half of the participants receive the drug and the other half gets a sugar pill called a placebo. And while this test is mostly about safety, having the control group helps the researchers begin to pick up clues about whether the drug is working as designed.

The groups are larger, with participants numbering in the hundreds, according to the FDA.

It is at this stage that the drug-approval process could end if the Trump administration picks a commissioner in favor of approving drugs only after they’ve been proven safe and not necessarily effective.

Based on the current clinical-trial process, there’s just a 30% chance of a drug moving from phase two to phase three, according to data from biotech trade organization BIO.

See the rest of the story at Business Insider

See Also:

9 at-home remedies that actually work

Psychologists have identified 10 factors that explain why and how we fall in love

6 strange things love does to your brain and body

SEE ALSO: One of the next epidemic-level chronic diseases doesn’t have any approved treatments — and it could ‘swamp the system’

DON’T MISS: Everyone wants a piece of the drug industry and it’s one reason prices are rising so fast

Trump is promising big changes at the FDA — here’s how drugs are approved today